ROPIVACAINE HYDROCHLORIDE

Search structure
Trade Names:
Synonyms:
Status: Approved (1996)
Entry Type: Small molecule
Molecule Category: Salt
UNII: V910P86109
Parent Compound: ROPIVACAINE

Structure
InChI Key NDNSIBYYUOEUSV-RSAXXLAASA-N
Smile CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C.Cl
InChI
InChI=1S/C17H26N2O.ClH/c1-4-11-19-12-6-5-10-15(19)17(20)18-16-13(2)8-7-9-14(16)3;/h7-9,15H,4-6,10-12H2,1-3H3,(H,18,20);1H/t15-;/m0./s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C17H27ClN2O
Molecular Weight 310.87
AlogP 3.51
Hydrogen Bond Acceptor 2.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 4.0
Polar Surface Area 32.34
Molecular species NEUTRAL
Aromatic Rings 1.0
Heavy Atoms 20.0

Pharmacology

Action Mechanism of Action Reference
BLOCKER Sodium channel alpha subunit blocker
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Transferase
- - - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Osteoarthritis 3 D010003 ClinicalTrials
Hallux Valgus 3 D006215 ClinicalTrials
Fractures, Bone 2 D050723 ClinicalTrials
Head and Neck Neoplasms 2 D006258 ClinicalTrials
Musculoskeletal Diseases 2 D009140 ClinicalTrials
Hernia, Inguinal 1 D006552 ClinicalTrials

Related Entries

Scaffolds

Parent

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Nervous system disorders
26.9
Injury, poisoning and procedural complications
14.21
General disorders and administration site conditions
8.59
Cardiac disorders
8.5
Respiratory, thoracic and mediastinal disorders
6.85
Vascular disorders
6.5
Skin and subcutaneous tissue disorders
4.4
Musculoskeletal and connective tissue disorders
3.8
Psychiatric disorders
3.77
Investigations
3.23
Eye disorders
2.69
Immune system disorders
2.55

Cross References

Resources Reference
ChEBI 60803
ChEMBL CHEMBL1889140
EPA CompTox DTXSID2048379
FDA SRS V910P86109
PubChem 53262295
SureChEMBL SCHEMBL236432
CONTENTS